Worldwide: Food and Drugs Law

A bill introduced in the Colorado Senate this session could meaningfully reshape how craft producers across the state share facilities, split costs, and bring new products to market.

What's new: In early February 2026, FDA announced it is taking issue with the use of the phrase "same active ingredient" in advertising for compounded drugs, saying it may confuse consumers.

An unusual lineup of states is jumping on board the Trump administration's "Make America Healthy Again" campaign. There are currently dozens of pending bills in state legislatures seeking to ban certain consumable...

The Trump Administration continues to advocate for "Most Favored Nation" (MFN) pharmaceutical drug pricing through executive action and voluntary agreements, but the Administration's high-profile deals may have limited impact. To date, 16 manufacturers have signed voluntary agreements to adopt MFN prices. These deals will only apply to state Medicaid programs and cash-paying consumers, which limits their impact.

On February 17, 2026, the U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP), chaired by Senator Bill Cassidy (R-LA), published a white paper outlining proposed...

On February 13, 2026, the state of Iowa filed an appellate brief with the United States Court of Appeals for the Eighth Circuit...

In legislation enacted on Feb. 3, 2026, Congress reauthorized the rare pediatric disease priority review voucher program, clarified the scope of orphan drug exclusivity...

We are excited to begin In the Public Interest's sixth season with the introduction of our new co-host Jekkie Kim. Jekkie is a corporate partner in WilmerHale's Palo Alto office who focuses on life sciences technology...

Recent developments at the federal legislative and regulatory levels signal a significant shift toward greater transparency requirements in the pharmacy benefit management (PBM) industry.